Beijing Tuohua Weiye Biotechnology

Beijing Tuohua Weiye Biotechnology is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the research and development of advanced immune cell therapies. The company primarily focuses on Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies, including various forms of leukemia and lymphoma. Its lead candidates, such as TH-001 and TH-002, target well-validated antigens like CD19 and BCMA and are currently undergoing clinical evaluation in Phase 1 and Phase 2 trials. Tuohua Weiye leverages its proprietary technology to enhance the persistence and efficacy of cell products while maintaining a manageable safety profile. The company maintains integrated R&D and manufacturing capabilities within the Beijing Economic-Technological Development Area to support its clinical pipeline and future commercialization efforts.